Keisuke Terayama
Overview
Explore the profile of Keisuke Terayama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
371
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aiba T, Hattori C, Sugisaka J, Shimizu H, Ono H, Domeki Y, et al.
PLoS One
. 2021 Nov;
16(11):e0260500.
PMID: 34843570
Although anti-PD-1/PD-L1 monotherapy has achieved clinical success in non-small cell lung cancer (NSCLC), definitive predictive biomarkers remain to be elucidated. In this study, we performed whole-transcriptome sequencing of pretreatment tumor...
2.
Ono K, Ono H, Toi Y, Sugisaka J, Aso M, Saito R, et al.
Cancer Med
. 2021 Jun;
10(14):4796-4804.
PMID: 34121358
Background: The association between the development of checkpoint inhibitor pneumonitis (CIP) with tumor response and survival has remained unclear so far. The aim of the present study was to evaluate...
3.
Sugisaka J, Toi Y, Taguri M, Kawashima Y, Aiba T, Kawana S, et al.
JMA J
. 2020 Dec;
3(1):58-66.
PMID: 33324776
Introduction: Immune checkpoint inhibitors (ICIs) can lead to immune-related adverse events (irAEs). A correlation between the development of irAEs and efficacy has been suggested; however, it is unclear whether there...
4.
Toi Y, Kimura Y, Domeki Y, Kawana S, Aiba T, Ono H, et al.
Sarcoidosis Vasc Diffuse Lung Dis
. 2020 Jun;
36(1):74-78.
PMID: 32476938
Background: We have often encountered adverse events requiring dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis. Objectives: The objectives of this study were to clarify the...
5.
Aso M, Toi Y, Sugisaka J, Aiba T, Kawana S, Saito R, et al.
Oncologist
. 2020 Mar;
25(3):e536-e544.
PMID: 32162801
Background: Anti-programmed cell death 1 antibody is a standard therapy for advanced non-small cell lung cancer (NSCLC). However, immune-related adverse events (irAEs), such as skin reactions, are frequently observed. Although...
6.
Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, et al.
JAMA Oncol
. 2018 Dec;
5(3):376-383.
PMID: 30589930
Importance: Administration of anti-programmed cell death protein 1 (anti-PD-1) is now standard therapy in advanced non-small cell lung cancer (NSCLC). However, immune checkpoint inhibitors, including anti-PD-1, have not been assessed...
7.
Toi Y, Sugawara S, Kawashima Y, Aiba T, Kawana S, Saito R, et al.
Oncologist
. 2018 Jun;
23(11):1358-1365.
PMID: 29934411
Background: Immune-related adverse events (irAEs) are frequently observed with nivolumab monotherapy. This study aimed to evaluate whether the development of irAEs correlates with treatment response in advanced non-small-cell lung cancer...
8.
Toi Y, Sugawara S, Kobayashi T, Terayama K, Honda Y
Int J Clin Oncol
. 2018 Jun;
23(6):1046-1051.
PMID: 29876691
Background: Diarrhea post-antibiotic use is primarily attributed to Clostridium difficile infection (CDI)-induced mucosal lesions, and evidence of CDI in patients undergoing chemotherapy without prior antibiotic treatment is also increasing. However,...